Ankyra Therapeutics is a clinical-stage biotech developing anchored-drug conjugates to trigger long lasting anti-tumor response without compromising safety.

Ankyra Therapeutics

Ankyra Therapeutics | 1,812 followers on LinkedIn. Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response | Ankyra is developing a novel approach for cancer treatment called Anchored Immunotherapy, promoting prolonged immune activation locally while limiting systemic toxicity.

Co-founder/Managing Partner, Borealis Ventures

Phil Ferneau

Experienced Quality Assurance professional

Dayna Resi

Lynn Nicole (Dickerson)

Chief Process and Manufacturing Officer at Ankyra Therapeutics

Greg Zarbis-Papastoitsis

Ankyra Therapeutics announces the first visceral tumor patient dosed #anchoredimmunotherapy #anchoreddrugconjugates https://shorturl.at/nclWG

Ankyra Therapeutics is excited to announce the appointment of Julia G. Butchko, Ph.D. and Tara Withington, CAE to the Ankyra Board of Directors. https://shorturl.at/UHkXq

Ankyra Therapeutics President and CEO Howard Kaufman will be speaking at today's SITC Summit on Intralesional Immunotherapy #SITC #Anchoredimmunotherapy #immunotherapy

Come see Ankyra Therapeutics Trial in Progress poster, A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors, at 9am CDT located at 158A #ASCO https://lnkd.in/ecSv2fxn

Ankyra Therapeutics President and CEO will be the featured speaker at Drug Discovery News upcoming webinar about Combination therapy for Cancer on April 18, 2024 at 1pm ET https://lnkd.in/exKhS5NZ

Ankyra Therapeutics has announced an exclusive licensing agreement for JEN-001 with Jenga Biosciences. https://lnkd.in/eXsQxYd2

Ankyra Therapeutics is excited to announce the first patient has been dosed in our Phase 1 clinical trial evaluating ANK-101, an Anchored Immune Medicine, for the treatment of solid tumors. Read more in the press release: https://rb.gy/n6vaw7

The Ankyra Therapeutics team proudly participated in the Life Science Cares Boston #Holidayhelpers program this holiday season.

This month, results from a preclinical study demonstrating potent anti-tumor activity of our lead program ANK-101 were published in the December issue of The Journal of Clinical Investigation Insight. Data from the study on ANK-101, a novel tumor-directed anchored immune medicine (AIM), demonstrated retention at the tumor site for approximately four weeks, overcoming the challenges of intratumoral injection. To read more and to view the paper, "Intratumoral aluminum hydroxide-anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment": https://lnkd.in/euwp_NEF

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 15, 2024 10:34 AM	2c41fccd
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 15, 2024 10:34 AM	896ba8c5
crunchbase trigger	general	Nov 15, 2024 10:34 AM	1c1463d1
crunchbase profile	general	Nov 15, 2024 7:14 PM	1f1d3046
li profile	general	Nov 15, 2024 10:34 AM	543291e4
translate crunchbase fundingrounds	general
peers	general	Nov 15, 2024 10:34 AM	9f154d9e
news basic	general	Nov 15, 2024 10:34 AM	abd96e23
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ANKY

COM:ANKYRATX

Ankyra Therapeutics